New cancer drug PEP08 enters first human trials for Tough-to-Treat tumors
NCT ID NCT06973863
Summary
This is the first study in people testing PEP08, a new oral cancer drug, for patients with advanced solid tumors that have a specific genetic change called MTAP deletion. The main goals are to find safe doses, see how the body processes the drug, and look for early signs that it might shrink tumors. The study will test PEP08 alone and later combined with another cancer treatment in adults whose cancer has progressed after standard therapies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
China Medical University Hospital
RECRUITINGTaichung, Taiwan
-
National Taiwan University Hospital
RECRUITINGTaipei, Taiwan
-
Taipei Veterans General Hospital
RECRUITINGTaipei, Taiwan
-
Westmead Hospital
RECRUITINGWentworthville, New South Wales, 2145, Australia
Conditions
Explore the condition pages connected to this study.